Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.

Proceedings of the National Academy of Sciences of the United States of America
Jynho KimPhilip A Beachy

Abstract

Aberrant Hedgehog (Hh) pathway activation has been implicated in cancers of diverse tissues and organs, and the tumor growth-inhibiting effects of pathway antagonists in animal models have stimulated efforts to develop pathway antagonists for human therapeutic purposes. These efforts have focused largely on cyclopamine derivatives or other compounds that mimic cyclopamine action in binding to and antagonizing Smoothened, a membrane transductory component. We report here that arsenicals, in contrast, antagonize the Hh pathway by targeting Gli transcriptional effectors; in the short term, arsenic blocks Hh-induced ciliary accumulation of Gli2, the primary activator of Hh-dependent transcription, and with prolonged incubation arsenic reduces steady-state levels of Gli2. Arsenicals active in Hh pathway antagonism include arsenic trioxide (ATO), a curative agent in clinical use for acute promyelocytic leukemia (APL); in our studies, ATO inhibited growth of Hh pathway-driven medulloblastoma allografts derived from Ptch+/-p53-/- mice within a range of serum levels comparable to those achieved in treatment of human APL. Arsenic thus could be tested rapidly as a therapeutic agent in malignant diseases associated with Hh pathway activati...Continue Reading

References

Aug 26, 1998·Reproductive Toxicology·J M DeSessoJ F Holson
Sep 25, 1999·Toxicological Sciences : an Official Journal of the Society of Toxicology·A F MachadoM D Collins
Jan 5, 2000·Oncogene·A C PorterR R Vaillancourt
Dec 4, 2001·Genes & Development·P W Ingham, A P McMahon
Jun 18, 2002·Nature Genetics·Michael D TaylorDavid Hogg
Aug 31, 2002·Science·David M BermanPhilip A Beachy
Oct 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·James K ChenPhilip A Beachy
Nov 5, 2002·Genes & Development·James K ChenPhilip A Beachy
Apr 8, 2003·Proceedings of the National Academy of Sciences of the United States of America·Juliet A WilliamsFrank Y Wang
Oct 31, 2003·Toxicologic Pathology·Paul B TchounwouJose A Centeno
Oct 16, 2004·Molecular Cancer·Tao ShengJingwu Xie
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dan Douer, Martin S Tallman
Sep 2, 2005·Nature·Kevin C CorbitJeremy F Reiter
Feb 7, 2006·Developmental Cell·Markku VarjosaloJussi Taipale
Dec 6, 2006·Cancer Research·David ShackelfordRuibao Ren
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Craig D PeacockWilliam Matsui
Apr 25, 2007·Oncogene·Y LeeP J McKinnon
May 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Matthias LauthRune Toftgård
Jul 17, 2007·Nature Medicine·Christine DierksMarkus Warmuth
Jul 21, 2007·Science·Rajat RohatgiMatthew P Scott
Dec 18, 2007·Oncogene·J P ZwernerW A May
Jan 1, 2008·Journal of Inorganic Biochemistry·Kirk T Kitchin, Kathleen Wallace
Mar 22, 2008·Chembiochem : a European Journal of Chemical Biology·Takahiro HosoyaMasami Ishibashi
Apr 15, 2008·Nature Cell Biology·Valérie Lallemand-BreitenbachHugues de Thé
Jun 21, 2008·Molecular Cancer Therapeutics·Koren K MannWilson H Miller
Aug 30, 2008·Nature·Robert L YauchFrederic J de Sauvage
Sep 17, 2008·Genes & Development·Markku Varjosalo, Jussi Taipale
Feb 5, 2009·The Journal of Biological Chemistry·Elspeth BeauchampAykut Uren
Feb 28, 2009·Proceedings of the National Academy of Sciences of the United States of America·Hua TianFrederic J de Sauvage
May 28, 2009·Journal of Medicinal Chemistry·Karen Miller-MoslinJoseph F Kelleher

❮ Previous
Next ❯

Citations

Mar 16, 2013·Annals of Hematology·Athena KritharisDaniel R Budman
Sep 4, 2012·Archives of Pharmacal Research·Jeong In YunJongkook Lee
Apr 23, 2013·Drugs·Joshua M Ruch, Edward J Kim
Oct 1, 2013·Nature Medicine·Jean B RegardYingzi Yang
Nov 10, 2013·Nature Medicine·Dereck AmakyeMarion Dorsch
May 27, 2011·Nature Reviews. Cancer·Jessica M Y Ng, Tom Curran
Dec 29, 2012·The Journal of Biological Chemistry·Wensheng YanXinbin Chen
Dec 7, 2013·Neuro-oncology·Tobey J MacDonaldRobert C Castellino
Oct 13, 2010·Toxicological Sciences : an Official Journal of the Society of Toxicology·Erik J TokarMichael P Waalkes
Nov 5, 2011·Genes & Development·R Tyler HillmanMatthew P Scott
Jun 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ross McMillan, William Matsui
Dec 25, 2010·The Journal of Clinical Investigation·Elspeth M BeauchampAykut Uren
Dec 25, 2010·The Journal of Clinical Investigation·G Praveen Raju
Feb 2, 2012·The Journal of Clinical Investigation·Maria KasperRune Toftgård
May 23, 2013·Infectious Agents and Cancer·Syed Hassan Abbas NaqviSyed Mumtaz Ali Naqvi
Apr 4, 2013·Breast Cancer Research : BCR·Mun HuiAlexander Swarbrick
Aug 2, 2012·The Oncologist·Solmaz SahebjamAlbiruni A Razak
Apr 14, 2012·OncoTargets and Therapy·Tara L Lin, William Matsui
May 27, 2014·Nature Genetics·Robert T SweeneyRobert B West
May 16, 2014·Journal of Gastrointestinal Cancer·Pochi R Subbarayan, Bach Ardalan
Oct 30, 2013·Oncogene·S-M HedeF J Swartling
Jun 22, 2014·Neuro-oncology·Mark W Kieran
Sep 10, 2014·Current Treatment Options in Oncology·Allison M MartinKenneth J Cohen
Jul 6, 2014·Leukemia & Lymphoma·Lingyun Geng, Xin Wang
Nov 15, 2011·Leukemia & Lymphoma·Li-Yuan BaiCheng-Wen Lin
Jan 9, 2013·Expert Opinion on Therapeutic Patents·Matthew Kyle Hadden
Oct 17, 2012·The Journal of Cell Biology·Scott X AtwoodAnthony E Oro
Jul 18, 2015·Genes·Emanuela Felley-BoscoMayura Meerang
May 23, 2014·Expert Opinion on Drug Discovery·Upasana Banerjee, Matthew Kyle Hadden
Apr 30, 2014·Expert Opinion on Emerging Drugs·Jil DreierRainer Kunstfeld
Dec 22, 2015·Cellular and Molecular Life Sciences : CMLS·Yiguo Hu, Shaoguang Li
Oct 8, 2013·The Journal of Thoracic and Cardiovascular Surgery·Min YouDao M Nguyen
Aug 23, 2012·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Karla C S QueirozMaikel P Peppelenbosch
Aug 22, 2012·Pharmacology & Therapeutics·Fergal C KelleherDavid M Thomas
Apr 24, 2012·Hematology/oncology Clinics of North America·Deirdre J Cohen
Jun 21, 2012·IUBMB Life·Sai-Juan Chen, Guang-Biao Zhou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CZI Human Cell Atlas Seed Network

The aim of the Human Cell Atlas (HCA) is to build reference maps of all human cells in order to enhance our understanding of health and disease. The Seed Networks for the HCA project aims to bring together collaborators with different areas of expertise in order to facilitate the development of the HCA. Find the latest research from members of the HCA Seed Networks here.